Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Baxter
Medtronic
Moodys
Mallinckrodt

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,323,884

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,323,884
Title:Isolated SNARE YKT6 genomic polynucleotide fragments from chromosome 7 and their uses
Abstract: The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.
Inventor(s): Ryan; James (Augusta, GA)
Assignee: Ryogen LLC (Suffern, NY)
Application Number:12/533,130
Patent Claims:1. An isolated acid molecule, said nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule 39,000 nucleotides in length which is at least 99% identical to SEQ ID NO:5 which encodes a polypeptide that has human SNARE YKT6 activity, wherein SEQ ID NO: 5 consists of a 5'-noncoding region shown in sequence segment 39000-15464 of SEQ ID NO:5, a 3'-non coding region shown in sequence segment 4319-1 of SEQ ID NO:6, exons regions shown in sequence segments 15463-15362, 12033-11950, 10215-10114, 9211-9107, 8466-8401, 5576-5475, 4352-4320 of SEQ ID NO:5 and intron regions shown in sequence segments 15361-12034, 11949-10216, 10113-9212, 9106-8467, 8400-5577, 5474-4353, of SEQ ID NO:5; (b) a fragment of (a), comprising at least nucleotides 15463-4320 of SEQ ID NO:5 which encodes a polypeptide having human SNARE YKT6 activity and; (c) a nucleic acid molecule which is a complement of the nucleic acid molecules specified in (a)-(b).

2. A nucleic acid construct comprising the nucleic acid molecule of claim 1.

3. An expression vector comprising the nucleic acid molecule of claim 1.

4. A recombinant host cell comprising the nucleic acid molecule of claim 1.

5. A method for obtaining a polypeptide having human SNARE YKT6 activity comprising: (a) culturing the recombinant host cell of claim 4 under conditions that provide for the expression of said polypeptide and (b) recovering said expressed polypeptide.

6. A composition comprising the nucleic acid molecule of claim 1 and a carrier.

7. A kit comprising the nucleic acid molecule of claim 1.

8. The kit according to claim 7, in which the nucleic acid molecule is labeled with a detectable substance.

9. A method of detecting the presence of a nucleic acid sequence of SEQ ID NO:5, its complementary sequence or unique fragment thereof in a sample, said method comprising contacting the sample with the nucleic acid molecule of claim 1 and determining whether the nucleic acid molecule binds to said nucleic acid sequence in the sample.

10. An isolated nucleic acid molecule consisting of a 5'-noncoding region shown in sequence segment 39000-15464 of SEQ ID NO:5, or a full complement of said isolated nucleic acid molecule.

11. An isolated nucleic acid molecule consisting of at least 2000 contiguous nucleotides in sequence segments of a 5'-noncoding region shown in sequence segment 39000-15464 of SEQ ID NO:5 or a full complement of said isolated nucleic acid molecule.

12. The isolated nucleic acid molecule of claim 1, wherein said isolated nucleic acid molecule is an RNA or DNA molecule.

13. The isolated nucleic acid molecule of claim 10, wherein said isolated nucleic acid molecule is an RNA or DNA molecule.

14. The isolated nucleic acid molecule of claim 11, wherein said isolated nucleic acid molecule is an RNA or DNA molecule.

15. A kit comprising the nucleic acid molecule of claim 10.

16. A kit comprising the nucleic acid molecule of claim 11.

Details for Patent 8,323,884

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2020-09-21
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2020-09-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Colorcon
Baxter
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.